MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1192/bjp.bp.112.108357

Медицинская библиотека · The British journal of psychiatry : the journal of mental science · 2012

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

Tohen Mauricio, McDonnell David P, Case Michael, Kanba Shigenobu, Ha Kyooseob, Fang Yi Ru, Katagiri Hideaki, Gomez Juan-Carlos

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Atypical antipsychotics are widely used in bipolar mania. However, the efficacy of atypical antipsychotics in bipolar depression has not been comprehensively explored.

AIMS: To evaluate olanzapine monotherapy in patients with bipolar depression.

METHOD: Patients with bipolar depression received olanzapine (5-20 mg/day, n = 343) or placebo (n = 171) for 6 weeks. The primary outcome was change from baseline to end-point in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary outcomes included: Clinical Global Impression - Bipolar Version (CGI-BP) scale, 17-item Hamilton Rating Scale for Depression (HRSD-17) and Young Mania Rating Scale (YMRS) scores, and the rate of response (≥50% reduction in MADRS at end-point), recovery (MADRS ≤12 for ≥4 weeks plus treatment completion) and remission (MADRS ≤8). The trial was registered with ClinicalTrials.gov (NCT00510146).

RESULTS

Olanzapine demonstrated: significantly greater (P<0.04) improvements on MADRS (least-squares mean change -13.82 v. -11.67), HRSD-17 and YMRS total scores and all CGI-BP subscale scores v. placebo; significantly (P≤0.05) more response and remission, but not recovery; significantly (P<0.01) greater mean increases in weight, fasting cholesterol and triglycerides; and significantly more (P<0.001) patients gained ≥7% body weight.

CONCLUSIONS

Olanzapine monotherapy appears to be efficacious in bipolar depression. Additional long-term studies are warranted to confirm these results. Safety findings were consistent with the known safety profile of olanzapine.

Для цитирования: Tohen Mauricio, McDonnell David P, Case Michael, Kanba Shigenobu, Ha Kyooseob, Fang Yi Ru, Katagiri Hideaki, Gomez Juan-Carlos. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.. The British journal of psychiatry : the journal of mental science. 2012. DOI: 10.1192/bjp.bp.112.108357.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.